Trial Profile
A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP015K Following Single Doses in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Peficitinib (Primary)
- Indications Rheumatoid arthritis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 03 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2014 New trial record